Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results

Detalhes bibliográficos
Principais autores:	Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Shreeves, G, Poupard, L, Walicke, P, Balkissoon, J, Chaplin, D, Rustin, G
Formato:	Conference item
Publicado em:	2009

Registros relacionados

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
por: Zweifel, M, et al.
Publicado em: (2011)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
por: Rustin, G, et al.
Publicado em: (2010)

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
por: Nathan, P, et al.
Publicado em: (2008)

Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer
por: Blagden, S, et al.
Publicado em: (2018)

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
por: Nathan, P, et al.
Publicado em: (2012)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
por: Rustin, G, et al.
Publicado em: (2003)

Evaluation of retinal nerve fibre layer and macular thickness pre-and post-chemotherapy with carboplatin and paclitaxel in patients with endometrial and ovarian cancer
por: Juen, Chin Ju
Publicado em: (2021)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
por: Galbraith, S, et al.
Publicado em: (2001)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
por: Lunt, S, et al.
Publicado em: (2011)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
por: Jane Lunt, S, et al.
Publicado em: (2011)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
por: Tozer, G, et al.
Publicado em: (2001)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
por: Brooks, A, et al.
Publicado em: (2003)

Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas
por: Jain, H, et al.
Publicado em: (2012)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
por: Meyer, T, et al.
Publicado em: (2009)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
por: Prise, V, et al.
Publicado em: (2002)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
por: Tozer, G, et al.
Publicado em: (2009)

Paclitaxel sensitivity of ovarian cancer can be enhanced by knocking down pairs of kinases that regulate MAP4 phosphorylation and microtubule stability
por: Yang, H, et al.
Publicado em: (2018)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
por: Mukherjee, S, et al.
Publicado em: (2017)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
por: Thomson, P, et al.
Publicado em: (2006)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence
por: Sandercock, J, et al.
Publicado em: (1998)

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.
por: Maxwell, R, et al.
Publicado em: (2002)

iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
por: Jiang, L, et al.
Publicado em: (2011)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
por: Mukherjee, S, et al.
Publicado em: (2015)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
por: Mukherjee, S, et al.
Publicado em: (2015)

The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.
por: Ahmed, A, et al.
Publicado em: (2007)

A novel salt inducible kinase 2 inhibitor, ARN-3261, sensitizes ovarian cancer cell lines and xenografts to carboplatin
por: Fan, D, et al.
Publicado em: (2021)

Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.
por: Xie, X, et al.
Publicado em: (2013)

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
por: Le, X, et al.
Publicado em: (2011)

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
por: Nathan, P, et al.
Publicado em: (2007)

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
por: Cesca, M, et al.
Publicado em: (2009)

On oxidation behaviour of platinum aluminide coated nickel based superalloy CMSX-(4)
por: Reed, R, et al.
Publicado em: (2009)

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
por: Patterson, D, et al.
Publicado em: (2012)

6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase-2 regulates TP53-dependent paclitaxel sensitivity in ovarian and breast cancers
por: Yang, H, et al.
Publicado em: (2019)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
por: Stratford, MR
Publicado em: (2008)

Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model
por: Wood, Joseph, et al.
Publicado em: (2016)

A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
por: Zhou, J, et al.
Publicado em: (2016)

Phase 1 study of HSP90 inhibitor ganetespib with pemetrexed and cisplatin/carboplatin chemotherapy for pleural mesothelioma
por: Fennell, D, et al.
Publicado em: (2018)

Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer
por: Tharmalingam, MD, et al.
Publicado em: (2020)

Targeting PFKFB4 in mitotically vulnerable ovarian cancer cells
por: Taylor, C
Publicado em: (2016)

Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs
por: Alexander, Sarah M., et al.
Publicado em: (2015)